Pityriasis Rubra Pilaris Clinical Trial
Official title:
Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
15 patients with PRP will be treated with ixekizumab for 24 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit and week-24 visit. 5 visits in between these times and one follow up visit may be performed by secure videoconferencing.
Pityriasis rubra pilaris (PRP) is a rare and poorly understood severe inflammatory skin
disease characterized by widespread (often full-body) redness and flaking of the skin,
painful thickening and cracking of the palms and soles, hair loss, crumbling nails, and
severe skin itching and burning.
There is no FDA-approved therapy for this rare disease and the commonly used medications do
not work for many patients. There is some evidence that IL-17 may be too high in the skin of
PRP patients. Ixekizumab is an injectable medication that blocks IL-17 and is FDA-approved
for psoriasis.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03975153 -
Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
|
Phase 2 | |
| Not yet recruiting |
NCT06444399 -
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
|
Phase 2 | |
| Terminated |
NCT00815633 -
A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris
|
Phase 4 | |
| Completed |
NCT03342573 -
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
|
Phase 1 |